Role of anti cholesterol medicine for fatty liver
Not Applicable
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2023/02/049958
- Lead Sponsor
- AIG Hospitals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age > 18 Years
BMI <23 kg/m2
Patient with fatty liver disease, chronic liver disease without ascites (Child Pugh score <8)
Exclusion Criteria
Decompensated cirrhosis
Allergy to Vitamin E or SAROGLITAZAR
BMI > 23 kg/m2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in liver stiffness measurement using transient elastography in patients in each groupTimepoint: 0,6 and 12 months
- Secondary Outcome Measures
Name Time Method to assess change in controlled attenuation parameter in each groupTimepoint: 0,6 and 12 months;to assess change in liver function testsTimepoint: 0,6 and 12 months;to assess the change in HOMA-IR score in each groupsTimepoint: 0,6 and 12 months;to assess the change in Lipid profile in each groupTimepoint: 0,6 and 12 months